Besides demonstrating the feasibility and safety of this treatment, with only grade 1–2 adverse effects reported, it was also shown that the combination of tumor exosomes with GM-CSF allowed for a more efficient induction of systemic anti-tumor immunity and CTL responses than the administration of the isolated tumor exosomes. The gene discussed is CSF2; the disease is neoplasm.